Press releases

and Orlando, FL (March 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) today welcomed the results of Johnson & Johnson's REALITY clinical trial, which reaffirmed the safety and efficacy of...

and Orlando, FL (March 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS V clinical trial, confirming the safety and efficacy of the TAXUS®...

(March 4, 2005) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has completed its acquisition of Advanced Stent Technologies, Inc. (AST) of Pleasanton, California, for an...

(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs...

(February 23, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the start of enrollment in the world's largest drug-eluting stent registry. The TAXUS OLYMPIC registry plans to...

(February 22, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific's...

(February 16, 2005) -- Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the Interventional Procedures Advisory Committee (IPAC) of the United Kingdom's National...

(February 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is...

and New York, NY (February 1, 2005) -- Boston Scientific Corporation (NYSE: BSX) today provided financial guidance for 2005 and announced financial goals for 2006 and 2007 at a meeting with...

(January 31, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed the initial launch of its TAXUS® Liberté™ paclitaxel-eluting coronary stent system. On...